open access

Vol 86, No 1 (2018)
REVIEWS
Published online: 2018-02-28
Submitted: 2017-12-18
Accepted: 2018-02-14
Get Citation

Dry powder inhalers — between the doctor and the patient

Andrzej Emeryk, M Pirożyński, J Emeryk-Maksymiuk
DOI: 10.5603/ARM.2017.0061
·
Pubmed: 29490421
·
Adv Respir Med 2018;86(1):44-52.

open access

Vol 86, No 1 (2018)
REVIEWS
Published online: 2018-02-28
Submitted: 2017-12-18
Accepted: 2018-02-14

Abstract

The article briefly presents currently accessible dry powder inhalers (DPI). Basing on the data from the literature, we discussed the
most common mistakes related to the utilisation of DPI as well as their clinical and economic consequences. We also extensively
analysed all factors that may influence the efficacy and safety of inhaler therapy of asthma and COPD, mostly with the use of
DPI. In addition, we indicated the potential to improve the efficacy of inhaler therapy from the doctor and COPD or asthma patient
perspective. We also presented a DPI choice algorithm including the patient’s preferences and competences.

Abstract

The article briefly presents currently accessible dry powder inhalers (DPI). Basing on the data from the literature, we discussed the
most common mistakes related to the utilisation of DPI as well as their clinical and economic consequences. We also extensively
analysed all factors that may influence the efficacy and safety of inhaler therapy of asthma and COPD, mostly with the use of
DPI. In addition, we indicated the potential to improve the efficacy of inhaler therapy from the doctor and COPD or asthma patient
perspective. We also presented a DPI choice algorithm including the patient’s preferences and competences.

Get Citation

Keywords

dry powder inhaler, Ellipta inhaler, asthma, COPD, patient, errors in inhalation

About this article
Title

Dry powder inhalers — between the doctor and the patient

Journal

Advances in Respiratory Medicine

Issue

Vol 86, No 1 (2018)

Pages

44-52

Published online

2018-02-28

DOI

10.5603/ARM.2017.0061

Pubmed

29490421

Bibliographic record

Adv Respir Med 2018;86(1):44-52.

Keywords

dry powder inhaler
Ellipta inhaler
asthma
COPD
patient
errors in inhalation

Authors

Andrzej Emeryk
M Pirożyński
J Emeryk-Maksymiuk

References (56)
  1. Sosnowski TR. Aerozole wziewne i inhalatory. WiChIP PW. 2012: Warszawa.
  2. Crompton GK. Dry powder inhalers: advantages and limitations. J Aerosol Med. 1991; 4(3): 151–156.
  3. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005; 50(9): 1209–1227.
  4. de Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017; 14(4): 499–512.
  5. Islam N, Gladki E. Dry powder inhalers (DPIs) ― a review of device reliability and innovation. Int J Pharm. 2008; 360(1-2): 1–11.
  6. Emeryk A, Bodajko-Grochowska A. Bartkowiak-Emeryk. Inhalatory suchego proszku ― jak ważna jest edukacja chorego? Alergia. 2013; 3: 17–21.
  7. Broeders ME, Molema J, Vermue NA, et al. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur Respir J. 2001; 18(5): 780–783.
  8. Atkins PJ. Dry powder inhalers: an overview. Respir Care. 2005; 50(10): 1304–1312.
  9. Newman S, Peart J. Dry powder inhalers. In: Newman S, Peart J. ed. Respiratory drug delivery: essential theory and practice. RDD Online, Richmond 2009: 257–308.
  10. Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis. 2017; 4(3): 217–224.
  11. Lexmond AJ, Kruizinga TJ, Hagedoorn P, et al. Effect of inhaler design variables on paediatric use of dry powder inhalers. PLoS One. 2014; 9(6): e99304.
  12. Pedersen S, Dubus JC, Crompton GK, et al. ADMIT Working Group. The ADMIT series--issues in inhalation therapy. 5) Inhaler selection in children with asthma. Prim Care Respir J. 2010; 19(3): 209–216.
  13. Loh CH, Peters SP, Lovings TM, et al. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause Rreadmissions. Ann Am Thorac Soc. 2017; 14(8): 1305–1311.
  14. Keating GM, Faulds D. Airmax: a multi-dose dry powder inhaler. Drugs. 2002; 62(13): 1887–95; discussion 1896.
  15. Emeryk A, Pirożyński M. [New dry powder inhalers]. Pneumonol Alergol Pol. 2015; 83(1): 83–87.
  16. Berkenfeld K, Lamprecht A, McConville JT. Devices for dry powder drug delivery to the lung. AAPS PharmSciTech. 2015; 16(3): 479–490.
  17. Emeryk A, Pirożyński M. Forspiro® - nowy inhalator suchego proszku. Czy zbliżamy się do ideału? Adv Respir Med. 2016; 84(Supp. VI): 64–69.
  18. Algorta J, Andrade L, Medina M, et al. Pharmacokinetic Bioequivalence of Two Inhaled Tiotropium Bromide Formulations in Healthy Volunteers. Clin Drug Investig. 2016; 36(9): 753–762.
  19. Buttini F, Hannon J, Saavedra K, et al. Accessorized DPI: a Shortcut towards Flexibility and Patient Adaptability in Dry Powder Inhalation. Pharm Res. 2016; 33(12): 3012–3020.
  20. Given J, Taveras H, Iverson H. Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter. Allergy Asthma Proc. 2016; 37(3): 199–206.
  21. van der Palen J, Thomas M, Chrystyn H, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016; 26: 16079.
  22. Grant AC, Walker R, Hamilton M, et al. The ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J Aerosol Med Pulm Drug Deliv. 2015; 28(6): 474–485.
  23. Jones S, Weuthen T, Harmer QJ, et al. P7 Assessing the intuitive ease of use of a novel dry powder inhaler, the Forspiro™ device, for asthma and COPD: Abstract P7 Table 1. Thorax. 2012; 67(Suppl 2): A66.2–A67.
  24. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008; 102(4): 593–604.
  25. Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017; 5(4): 1071–1081.e9.
  26. Westerik JAM, Carter V, Chrystyn H, et al. Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting. J Asthma. 2016; 53(3): 321–329.
  27. Sanchis J, Gich I, Pedersen S, et al. Aerosol Drug Management Improvement Team (ADMIT). Systematic review of errors in inhaler use: has patient technique improved over tme? Chest. 2016; 150(2): 394–406.
  28. Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003; 16(3): 249–254.
  29. Chrystyn H, van der Palen J, Sharma R, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017; 27(1): 22.
  30. Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008; 75(1): 18–25.
  31. Sulaiman I, Seheult J, Sadasivuni N, et al. The impact of common inhaler errors on drug delivery: investigating critical errors with a dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2017; 30(4): 247–255.
  32. Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017; 49(2).
  33. Lewis A, Torvinen S, Dekhuijzen PNR, et al. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries. BMC Health Serv Res. 2016; 16: 251.
  34. Lewis A, Torvinen S, Dekhuijzen PNR, et al. Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®. Respir Med. 2017; 129: 179–188.
  35. Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J. 2009; 18(4): 243–249.
  36. van Aalderen WM, Garcia-Marcos L, Gappa M, et al. How to match the optimal currently available inhaler device to an individual child with asthma or recurrent wheeze. NPJ Prim Care Respir Med. 2015; 25: 14088.
  37. Laube BL, Janssens HM, de Jongh FHC, et al. European Respiratory Society, International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011; 37(6): 1308–1331.
  38. Lavorini F, Levy ML, Corrigan C, et al. ADMIT Working Group. The ADMIT series ― issues in inhalation therapy. Training tools for inhalation devices. Prim Care Respir J. 2010; 19(4): 335–341.
  39. Ari A. Patient education and adherence to aerosol therapy. Respir Care. 2015; 60: 941–955.
  40. Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis. 2017; 12: 59–71.
  41. Emeryk A, Pirożyński M, Mazurek H. Polski przewodnik inhalacyjny. Via Medica, Gdańsk 2015: 1–22.
  42. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017; 389(10082): 1919–1929.
  43. Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017; 196(4): 438–446.
  44. Roche N, Scheuch G, Pritchard JN, et al. Patient focus and regulatory considerations for inhalation device design: report from the 2015 IPAC-RS/ISAM Workshop. J Aerosol Med Pulm Drug Deliv. 2017; 30(1): 1–13.
  45. McCormack PL, Plosker GL. Inhaled mometasone furoate: A review of its use in persistent asthma in adults and adolescents. Drugs. 2006; 66(8): 1151–1168.
  46. https://ec.europa.eu/health/documents/community-register/2015/20151106133423/anx_133423_pl.pdf.
  47. http://www easyhaler pl/Easyhaler_Global/EasyhalerPL/produkty%20spc%20pil/BUDESONIDE%20EH%20PIL%202012 09 19%20var.
  48. https://www.leki-informacje.pl/sites/default/files/indeks_lekow/ulotki/Ulotka-AsmanexTwisthaler400.pdf.
  49. https://www.leki-informacje.pl/sites/default/files/indeks_lekow/ulotki/Ulotka-Fostex_Nexthaler.pdf.
  50. https://www.dokteronline.com/pils/pl/patient_information_leaflet-1783-flixotide-pl-dysk.pdf-1352727721.pdf.
  51. https://www astrazeneca pl/content/dam/az-pl/ulotki-lekow/PIL_Oxis(4,5)_2016-08-25(CDS_2015pdf.
  52. Svedsater H, Jacques L, Goldfrad C, et al. Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma. NPJ Prim Care Respir Med. 2014; 24: 14019.
  53. Broeders ME, Sanchis J, Levy ML, et al. ADMIT Working Group. The ADMIT series--issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Prim Care Respir J. 2009; 18(2): 76–82.
  54. Virchow JC, Crompton GK, Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008; 102(1): 10–19.
  55. Vincken W, Dekhuijzen PnR, Barnes P, et al. ADMIT Group. The ADMIT series - Issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J. 2010; 19(1): 10–20.
  56. Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J. 2009; 18(4): 243–249.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl